Study Phase 3

Open-label Study Exploring a Switching Regimen From Depot Neuroleptics to Risperidone Depot Microspheres

  • 1 CSR Summary Not Available
  • 1 NCT Number Not Available
  • 1 Primary Citation Not Available
  • Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment160% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-INT-85Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.